DexCom, Inc. Forecast, price target & analysts
DexCom, Inc. Target price 2026 - Analyst rating & recommendation
DexCom, Inc. Classifications & Recommendation
DexCom, Inc. Price Target
| Target Price | $96.90 |
| Price | $78.62 |
| Potential | 23.25% |
| Number of Estimates | 31 |
| 31 Analysts have issued a price target DexCom, Inc. 2027 . The average DexCom, Inc. target price is $96.90. This is 23.25% higher than the current stock price. The highest price target is $120.75 53.59% , the lowest is $75.75 3.65% . | |
| A rating was issued by 36 analysts: 31 Analysts recommend DexCom, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the DexCom, Inc. stock has an average upside potential 2027 of 23.25% . Most analysts recommend the DexCom, Inc. stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2030
31 Analysts have issued a sales forecast DexCom, Inc. 2026 . The average DexCom, Inc. sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
27 Analysts have issued an DexCom, Inc. EBITDA forecast 2026. The average DexCom, Inc. EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
32 DexCom, Inc. Analysts have issued a net profit forecast 2026. The average DexCom, Inc. net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
Current DexCom, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Buy
➜
Buy
|
Unchanged | Oct 12 2026 |
| Barclays |
➜
Overweight
|
Initiated | Oct 07 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 01 2026 |
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Sep 18 2026 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Sep 18 2026 |
| Argus Research |
Buy
➜
Buy
|
Unchanged | Aug 04 2026 |
| Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Aug 03 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BTIG:
Buy
➜
Buy
|
Oct 12 2026 |
|
Initiated
Barclays:
➜
Overweight
|
Oct 07 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 01 2026 |
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Sep 18 2026 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Sep 18 2026 |
|
Unchanged
Argus Research:
Buy
➜
Buy
|
Aug 04 2026 |
|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Aug 03 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
